Table 3.
miRNA signatures and their roles in predicting outcome in breast cancer patients.
| Author | Year | Country | Tissue | N | miRNA Expression Signatures |
|---|---|---|---|---|---|
| Lai [74] |
2019 | China | Tumour & TAN | 1044 | Six miRNA signatures (miR-147b, miR-549a, miR-4501, miR-4675, miR-6715a and miR-7974) predicted OS at 5 years (AUC: 0.789). |
| Hong [75] | 2020 | China | Tumour | 111 | Eight miRNA expression signatures (miR-139-5p, miR-10b-5p, miR-486-5p, miR-455-3p, miR-107, miR-146b-5p, miR-324-5p and miR-20a-5p) predicted relapse and prognosis in TNBC (AUC: 800). |
| Cheng [76] |
2018 | China | Tumour & TAN | 1207 | Three miRNA expression signatures (including miR-133a-2, miR-204 and miR-301b) independently predicted OS (HR: 1.638; 95% CI: 1.147–2.339). |
| Shi [77] |
2018 | China | Tumour | 1098 | Three multi-miRNA signatures including miR-16-2, miR-31 and miR-484 predicted OS (AUC: 690). |
| Andrade [78] |
2020 | Brazil | Tumour | 185 | Four miRNA expression panels (miR-221, miR-1305, miR-4708 and RMDN2) substratified TNBC patients into high- and low-risk groups and independently predicted OS (HR: 0.32; 95% CI: 0.11–0.91). |
| Wu [79] |
2020 | China | Tumour & TAN | 199 | Aberrant expression levels of three miRNA (miR-21-3p, miR-200b-5p and miR-659-5p) independently predicted OS (HR: 7.396; 95% CI: 1.590–34.411). |
| Tang [80] |
2019 | China | Tumour | 1098 | Seventeen miRNA panels were constructed to predict OS, and a 13-miRNA signature predicted RFS. |
| Farina [81] |
2017 | US | Tumour | 48 | Six miRNA panels (miR-3124-5p, miR-1184, miR-4423-3p, miR-4529-5p, miR-7855-5p and miR-4446-3p), which predicted OS (AUC: 0.896; CI: 0.804–0.988). |
| Li [82] |
2018 | China | Serum | 386 | Four miRNA signatures (miR-16-5p, miR-17-3p, miR-451a and miR-940) predicted 1-year and 2-year predicted OS (AUC: 0.80 and 0.74, respectively) for metastatic HER2+ breast cancers. |
| Rohan [83] | 2019 | US | Tumour | 530 | Thirteen miRNA expression panels were designed to predict breast cancer recurrence (AUC: 0.67; CI: 0.58–0.795). |
N, number; TAN, tumour-associated normal; OS, overall survival; AUC, area under the curve; TNBC, triple-negative breast cancer; HR, hazard ratio; CI, confidence interval; RFS, recurrence-free survival; US, United States; HER2, human epidermal growth factor receptor-2.